Science bounties

Produce a traceable evidence map showing how far two published bacterial sensing studies support the Living Medicine concept. The useful result is an explicit boundary between demonstrated sensing, demonstrated therapeutic output, modeling, and unproven claims about autonomous treatment in patients.

Build a reproducible endpoint-design calculator from two published RTB101 trials. Quantify how observed event incidence, endpoint composition and baseline-risk uncertainty change the sample size needed for a future randomized trial. This addresses efficacy measurement and planning, separately from adverse-event detection or any claim that mTOR inhibition extends healthy life.

Build a reproducible benchmark comparing simple receptor-signaling models against a mean-only baseline for published mouse head-twitch response magnitude. Test both held-out compounds and transfer between the study's two compound panels. The useful outcome is a bounded decision about what evidence a computational neuropharmacology forecast should require, including a finding that no tested model improves reliably on the baseline.

Build a reproducible shortlist of BCL11A enhancer variants for endogenous functional validation using published saturation-mutagenesis reporter measurements. Quantify how barcode support, multiple testing and effect-size thresholds change the shortlist. A result finding no defensible robust candidates is eligible.

Reanalyze public TAK-925 response curves at OX1R and OX2R to determine when a subtype-selectivity ratio is identifiable and when only a bound or an inconclusive result is justified. Deliver a reproducible quantitative decision aid for interpreting the OX2R-004 program's proposed OX1R counter-screen.

Reanalyze public mouse cecal-metabolite measurements to identify whether early-life-stress-associated differences recur in descendants once cage, litter, experimental batch and multiple comparisons are considered. Deliver reproducible effect estimates and a defensible list of candidates for mechanistic follow-up—or a supported conclusion that none can yet be prioritized.

Reanalyze the public processed human expression matrix from GSE107063 to identify reproducible signals associated with soft gel, intermediate gel and glass culture. Deliver a benchmark that helps a synthetic tumour-microenvironment project decide which transcript-level changes warrant validation when selecting culture stiffness. A complete result showing instability or insufficient evidence is eligible; novel biomarkers are not required.

Deliver a decision-ready validation design for a STAT6 small-molecule screen: separate evidence of direct binding, cellular pathway modulation and disease-relevant activity, and specify how ambiguous or contradictory results affect advancement. Ground the design in two fixed public studies of AS1517499. This is a remote experimental-design deliverable; no experiment, novel binder or proprietary prediction is required or claimed.

Build a reproducible missing-outcome sensitivity analysis for the 2014 randomized trial of Lactobacillus reuteri DSM 17938 in infant colic. Deliver a decision brief identifying which treatment and subgroup claims the aggregate evidence can support, and which diary-retention uncertainties should shape a future objectively measured trial. A negative or inconclusive conclusion is eligible.

Produce a reproducible aggregate-data audit of cross-population evidence for BCL11A as a sickle-cell research target. Determine which conclusions about direction, magnitude and transferability are supported by the fixed studies below, and which remain unresolved. A well-supported negative or inconclusive conclusion is eligible.

Review public methodological evidence for ipSAE, interface predicted TM score, and PRODIGY predicted ΔG, then assess which interpretations of the posted shortlist are defensible.

Test whether the public post and final-results comment consistently report the eight designs, four gate-passed entries, ranks, engines, clusters, and prediction scores.